FACTORS ASSOCIATED WITH ORAL BISPHOSPHONATE ADHERENCE IN OLDER ADULTS WITH OSTEOPOROSIS AT UNIVERSITY MEDICAL CENTER HCMC
Main Article Content
Abstract
Objective: This study aims to identify factors associated with adherence to oral bisphosphonate therapy in patients aged ≥60 years with osteoporosis, using the Vietnamese version of the MARS-5 scale, to inform strategies for improving treatment effectiveness in Vietnam.
Methods: A cross-sectional study was conducted at the University Medical Center Ho Chi Minh City between November 2022 and April 2023, enrolling 172 outpatients aged ≥60 years diagnosed with osteoporosis and receiving oral bisphosphonates. Medication adherence was assessed using the validated Vietnamese version of the MARS-5 questionnaire. Demographic, clinical, and knowledge-related variables were collected. Univariate and multivariate logistic regression analyses were performed to identify independent factors associated with adherence.
Results: Among 172 patients (149 females, 23 males; mean age 68.7 ± 6.9 years), multivariate analysis revealed three independent factors significantly associated with adherence: treatment duration ≥12 months (p < 0.001), lack of knowledge about the benefits of medication (p = 0.017), and lack of awareness of fracture complications of osteoporosis (p = 0.022).
Conclusion: Adherence to oral bisphosphonate therapy in older adults is influenced by treatment duration and patient knowledge regarding medication benefits and fracture complications. Regular screening using the MARS-5 scale and enhanced patient education are essential to improve adherence and prevent osteoporotic fractures.
Article Details
Keywords
Osteoporosis, Oral bisphosphonate, Medication adherence, MARS-5, Older adults.
References
[2] Gustafsson M, Abramsson L. Adherence to Bisphosphonates among People Admitted to an Orthopaedic and Geriatric Ward at a University Hospital in Sweden. Pharmacy 2018;6(1):20. (In ENG). DOI: 10.3390/pharmacy6010020
[3] Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. Journal of the American Pharmacists Association : JAPhA 2017;57(4):503-509. (In eng). DOI: 10.1016/j.japh.2017.05.003.
[4] Gonnelli S, Caffarelli C, Letizia Mauro G, et al. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. Aging clinical and experimental research 2019;31(11):1541-1547. (In eng). DOI: 10.1007/s40520-019-01205-7.
[5] Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporosis International 2010;21(11):1899-1909. (In ENG). DOI: 10.1007/s00198-009-1141-5.
[6] Horne R, Weinman J. Self-regulation and Self-management in Asthma: Exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication. Psychology & Health 2002;17(1):17-32. (In ENG). DOI: 10.1080/08870440290001502.
[7] Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. Journal of acquired immune deficiency syndromes (1999) 2007;45(3):334-41. (In eng). DOI: 10.1097/QAI.0b013e31806910e3.
[8] Solomon DH, Iversen MD, Avorn J, et al. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Archives of internal medicine 2012;172(6):477-83. (In eng). DOI: 10.1001/archinternmed.2011.1977.